Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(3):168-172
DOI: 10.5428/pcar20180302
Survey on the current situation of therapeutic drug monitoring and gene test for personalized medication of 187 hospitals in China
1. BIAN JiaMing1(1.Department of Pharmacology, Army General Hospital of PLA, Beijing 100700,China bianbenjamin@163.com)
2. CHEN Yan1(1.Department of Pharmacology, Army General Hospital of PLA, Beijing 100700,China )
3. AN GuangWen2( 2. Department of Drugs and Apparatuses, No.261 Hospital of PLA, Beijing 100094,China )
4. ZHAO WeiJuan1(1.Department of Pharmacology, Army General Hospital of PLA, Beijing 100700,China )
5. YANG Fan1(1.Department of Pharmacology, Army General Hospital of PLA, Beijing 100700,China )
6. LIANG Hong1(1.Department of Pharmacology, Army General Hospital of PLA, Beijing 100700,China )
ABSTRACT  Objective: To investigate the current situation of therapeutic drug monitoring (TDM) and gene test for personalized medication (GTPM) delivered by hospitals in China. Methods: Questionnaire forms were designed, issued, submitted and analyzed by mobile Internet platform. Results: The distribution of retrieved valid questionnaires covered all the provinces of mainland China, except Hainan. National tertiary hospitals involved in the survey accounted for 90%. About 71% of the hospitals carried out TDM, in which sodium valproate, cyclosporine and tacrolimus were predominant test drugs. About 48% of the hospitals performed GTPM, in which clopidogel, warfarin and folic acid-related gene polymorphism sites were predominant test genes. Only about 70% of the surveyed hospitals held inter-sectional laboratory test quality evaluations of TDM and GTPM. Conclusion: The questionnaire survey truly reflected the current situation of personalized medication test in Chinese hospitals, revealed deficiency in awareness of quality control and incompliance of GTPM regulations, and different charging standards of medical test items. Therefore, the paper put forward recommendations for more strict management or supervision by related health administrations.
Welcome to PCAR! You are the number 331 reader of this article!
Please cite this article as:
BIAN JiaMing1,CHEN Yan1,AN GuangWen2,ZHAO WeiJuan1,YANG Fan1,LIANG Hong1,. Survey on the current situation of therapeutic drug monitoring and gene test for personalized medication of 187 hospitals in China[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(3): 168-172.
References:
1. YU LiHua, GUAN LingXian, HE YouJian, et al. Efficacy of treatment of patients with advanced refractory non-Hodgkin’s lymphoma using high dose methotrexate-citrovorum factor rescue method under serum methotrexate concentration monitoring[J]. Cancer, 1984,3(2):116-119.In Chinese with English abstract.
2. ZHANG ZhiPing, CHEN Xin, LI MingFeng. Blood drug concentration monitoring of six cases treated with high dose methotrexate[J]. Chin Hosp Pharm J, 1984,4(3):20-23.In Chinese.
3. WANG Li, XU XiaoWei. The significance of drug related gene detection for clinical rational use of drugs[J]. Chin Hosp Pharm J, 2008,28(21):1865-1868. In Chinese.
4. YANG XiaoYuan, MIAO Miao, LIU Jun. Involvement of clinical pharmacists in individualized treatment for a patient with atrial fibrillation and gout based on gene detection[J]. Chin J Clin Ration Drug Use, 2017,10(4A):108-109. In Chinese.
5. BIAN JiaMing, DING YuanYuan, YANG Fan, et al. Gene-directed personalized medication and clinical practice in the General Hospital of Beijing Military Command of PLA[J]. Pharm Care Res, 2014,14(3):161-165. In Chinese with English abstract.
6. Clinical Pharmacology Group,Pediatric Branch of Chinese Medical Association. Expert consensus on therapeutic drug monitoring of children[J]. Chin J Pediatr, 2015, 53(9):650-659. In Chinese.
7. CHEN YaoLong, CHEN Ken, YE ZhiKang, et al. Development of Chinese practice guidelines on therapeutic drug monitoring of vancomycin[J].Chin J Evid-based Med, 2015, 15(2):236-239. In Chinese with English title.
8. Patsalos P N, Berry D J, Bourgeois B F D, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring:a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies[J]. Epilepsia, 2008, 49(7):1239-1276.
9. Holt D W, Armstrong V W, Griesmacher A, et al. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group on immunosuppressive drug monitoring[J]. Ther Drug Monit, 2002, 24(1):59-67.
10. HUANG Liang, ZHANG LingLi, LI YouPing, et al. Current status of guidelines for therapeutic drug monitoring: an evidence-based evaluation[J]. Chin J Evid-based Med, 2016,16(4):451-459. In Chinese with English abstract.
11. WANG Jing, LIU Lu, ZHENG Heng, et al. Research progress in therapeutic drug monitoring[J]. Chin Hosp Pharm J, 2017,37(1):1-8. In Chinese with English abstract.
12. YAN Ying, ZHANG ShunLi, ZHONG Kun, et al. Analysis of external quality assessment results for therapeutic drug monitoring from 2010 to 2012[J]. Chin J Pharmacovigil, 2013,10(12):755-759. In Chinese with English abstract.
13. National Health and Family Planning Commission. Medical Institutions Clinical Gene Amplification Management Measures[EB/OL].(2010-12-10)[2018-03-14].http://www.nhfpc.gov.cn/mohyzs/s3586/ 201012/ 49981.shtml. In Chinese.
14. Mega J L, Hochholzer W, Frelinger A L Ⅲ, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease[J]. JAMA, 2011, 306(20):2221-2228.
15. Kim H S, Cho D Y, Park B M, et al. The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration[J]. J Clin Pharmacol,2014, 54(8):850-857.
16. Bauer T,Bouman H J,van Werkum J W,et al.Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel:systematic review and meta-analysis[J].BMJ,2011,343:d4588 doi:10.1136/bmj.d4588.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口